NDUFA2 and rectum adenocarcinoma: On the other hand, in rectum adenocarcinoma, the upregulation of NDUFA2 was a highly unfavorable factor, presenting a 19% 5-year survival rate in comparison to 67% for the NDUFA2 low-expression cohort.